Back to Ask the Diabetes Team Ask the Diabetes Team

From Dublin, Ireland:

Is there any way of avoiding loss of fatty tissue around the insulin injection area? Are there areas of the body where this condition is less likely to occur? My nephew is 5 years old and has started to develop high loss of tissue on his upper legs. He has type 1 insulin dependent diabetes. I have seen your answer to the question from the person in Orlando, Florida, but unfortunately you did not elaborate on the longer term affects of this condition or if it can be avoided.


Lipoatrophy used to more commonly seen before the purified insulins and human insulins became available. We still see lipoatrophy occasionally , even with human insulin. You can even have lipoatrophy in areas away from the actual shot locations.

As far as I know, there is nothing that can be done. There was a case report in Diabetes Care a few years ago which stated that using a jet injector helped, but I haven't heard more about this. We used to inject just around the atrophied areas to try to build up the area (hypertrophy), but this technique did not always work.

I usually recommend that people use their buttocks for their shots, where the lipoatrophy may not be as much of a problem cosmetically.


Original posting 3 Sep 1999
Posted to Blood Tests and Insulin Injections


  Back to Ask the Diabetes Team Return to the Top of This Page

Last Updated: (none)
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.